

UPDATE ON MEDICINES USED IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY



Medicines used in hereditary transthyretin amyloidosis in adult patients with Stage 1 or Stage 2 polyneuropathy

Reimbursed indication:
Patisiran (Onpattro®) and **vutrisiran (Amvuttra®)** are indicated for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
Inotersen (Tegsedi®) is indicated for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis.

Medicine	Patient population	Route of administration	Dose
Patisiran	Adults < 100 kg	IV infusion	300 mcg per kg body weight once every three weeks
Patisiran	Adults ≥ 100 kg	IV infusion	30 mg once every three weeks
Vutrisiran	Adult patients	SC injection	25 mg once every three months
Inotersen	Adult patients	SC injection	284 mg once every week (on the same day each week)



4

Total number of approved prescribers



65 years

Mean age of applicants



32

Total number of applications by October 2025



Medicines Management Programme

IV: Intravenous, kg: kilogram, mcg: microgram, mg: milligram, sc: subcutaneous

Medicinal Product	Ex-Factory price
Onpattro® 2mg/ml concentrate for solution for infusion (1 x 5 ml vial)	€8,074.94*
Amvuttra® 25mg solution for injection (1 x 25 mg/0.5 ml PFS)	€95,137.66*

Mg: milligram; ml: millilitre; PFS: pre-filled syringe

Medicinal Product	Reimbursement price*
Tegsedi® 284 mg solution for injection (4 x 1.5 ml PFS)	€23,613.11

Mg: milligram; ml: millilitre; PFS: pre-filled syringe

Data used: HSE Medicines Management Programme Managed Access Protocols, reimbursement applications data.
 *Information correct as at October 2025. Please refer to the HSE managed access protocol for medicines used in hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy for more information, available at www.hse.ie/mmp.

The HSE reimburse three medicines for hereditary transthyretin amyloidosis (hATTR) in adults with stage 1 or stage 2 polyneuropathy subject to a managed access protocol (MAP). The first MAP for a medicine for the treatment of hATTR with polyneuropathy was for patisiran, introduced in October 2021. This was followed by a MAP for inotersen in October 2022. A combined MAP for all medicines used in hATTR with polyneuropathy was developed with the reimbursement of vutrisiran in May 2024. The aim of this MAP is to provide patients with hATTR with polyneuropathy with access to these high-cost treatments.

Patisiran (Onpattro®) and vutrisiran (Amvuttra®) are available under hospital pricing approval and inotersen (Tegsedi®) is available under the High Tech Arrangement.

To date, the HSE have approved four prescribers under these protocols. By October 2025, 32 applications for these medicines were submitted to the HSE Medicines Management Programme. The mean age of applicants was 65 years at date of application.

October 2025

HSE Medicines Management Programme.